Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy

Gynecologic Oncology

Volumn 131, Issue 2, 2013, Pages 437-444

  Greimel, Elfriede ^a   Kristensen, Gunnar B ^b   Van Der Burg, Maria E L ^c   Coronado, Pluvio ^d   Rustin, Gordon ^e   Del Rio, Angel Sanchez ^f   Reed, Nicholas S ^g   Nordal, Randi R ^h   Coens, Corneel ⁱ   Vergote, Ignace ^j  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e MOUNT VERNON HOSPITAL   (United Kingdom)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^h UNIVERSITY OF BERGEN   (Norway)

ⁱ EORTC DATA CENTER   (Belgium)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Gynecologic oncology; Ovarian cancer; Patient reported outcomes; Phase III trial; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PAIN; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; INTERMETHOD COMPARISON; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PAIN ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE PAIN; PRIMARY DEBULKING SURGERY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOCIAL INTERACTION; SYMPTOM; TREATMENT DURATION;

GYNECOLOGIC ONCOLOGY; OVARIAN CANCER; PATIENT-REPORTED OUTCOMES; PHASE III TRIAL; QUALITY OF LIFE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE;

EID: 84886099822     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.08.014     Document Type: Article

References (36)

1. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of Cancer Cases Incidence and Mortality in Europe in 2008 Eur J Cancer 46 2008 765 781
2. R.F. Ozols Treatment goals in ovarian cancer Int J Gynecol Cancer 15 Suppl. 1 2005 3 11
3. S. Pignata, G. Scambia, G. Ferrandina, A. Savarese, R. Sorio, E. Breda, V. Gebbia, and P. Musso Carboplatin plus paclitaxel versus carboplatin liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial J Clin Oncol 29 2011 3628 3635
4. A. du Bois, and J. Pfisterer Future options for first-line therapy of advanced ovarian cancer Int J Gynecol Cancer 15 2005 42 50
5. G.J. Rustin, I. Vergote, E. Eisenhauer, E. Pujade-Lauraine, M. Quinn, and T. Thigpen 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 Suppl. 8 2005 viii7 viii12
6. W.J. Hoskins, B.N. Bundy, J.T. Thigpen, and G.A. Omura The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian carcinoma:a Gynecologic Oncology Group study Gynecol Oncol 47 1992 159 166
7. W.J. Hoskins, W.P. McGuire, M.F. Brady, H.D. Homesley, W.T. Creasman, and M. Berman The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residucal epithelial ovarian carcinoma Am J Obstet Gynecol 170 1994 974 979
8. I. Vergote, I. De Wever, W. Tjalma, M. Van Gramberen, J. Decloedt, and P. van Dam Nedoadjuvant chemotherapyor priary debulking surger in advanced ovarian carcinoma: a prospective analysis of 285 patients Gynecol Oncol 71 1998 431 436
9. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259
10. A. du Bois, A. Reuss, P. Harter, E. Pujade-Lauraine, I. Ray-Coquard, and J. Pfisterer Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospective randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Educes des Cancers de L'Ovaire (GINECO) Cancer 115 2009 1234 1244
11. M.E. van der Burg, M. van Lent, M. Buyse, A. Kobierska, N. Colombo, and G. Favalli The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer N Engl J Med 332 1995 629 634
12. J.H. Jacob, D.M. Gershenson, M. Morris, L.J. Copeland, T.W. Burke, and J.T. Wharton Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer Gynecol Oncol 42 1991 146 150
13. P.E. Schwartz, J.T. Chambers, and R. Makuch Neoadjuvant chemotherapy for advanced ovarian cancer Gynecol Oncol 53 1994 33 37
14. I.B. Vergote, I. De Wever, J. Decloedt, W. Tjalma, M. Van Gramberen, and P. van Dam Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer Semin Oncol 27 Suppl. 7 2000 31 36
15. Ovarian cancer: National Cancer Institute. http://www.cancer.gov/ cancertopics/types/ovarain/.
16. A. Bezjak, D. Tu, M. Bacon, D. Osoba, B. Zee, and G. Stuart Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in randomized study J Clin Oncol 22 2004 4595 4603
17. E.R. Greimel, V. Bjelic-Radisic, J. Pfisterer, F. Hilpert, F. Daghofer, and E. Pujade-Lauraine Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel J Clin Oncol 24 2006 579 586
18. L. Wenzel, H.Q. Huang, B.J. Monk, P.G. Rose, and D. Cella Quality of life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study J Clin Oncol 24 2005 5605 5612
19. G. Rustin, M.E.L. van der Burg, and C. Clare Griffin Early versus delayed treatment of relapsed ovarian cancer Lancet 377 2011 380 381
20. I. Vergote, C.G. Tropé, F. Amant, T. Ehlen, N.S Reed, and A. Casado Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 2010 943 953
21. N.K. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, and N.J. Duez The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
22. P. Fayers, N. Aaronson, K. Bjordal, M. Groenvold, D. Curran, and A. Bottomley EORTC QLQ-C30 Scoring Manual 3rd ed. 2001 EORTC publications Brussels
23. D. Osoba, G. Rodrigues, J. Myles, B. Zee, and J. Pater Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 1998 139 144
24. H. Akaike Information Measures and Model Selection 44 1983 International Statistical Institute 91 277
25. D. Fairclough Design and Analysis of Quality of Life Studies in Clinical Trials 2002 Chapman & Hall New York
26. B. Holzner, G. Kemmler, V. Meraner, A. Maislinger, M. Kopp, and T. Bodner Fatigue in ovarian carcinoma patients: a neglected issue Cancer 97 2003 1564 1572
27. S.R. Land, M.W. Ritter, J.P. Costantino, T.B. Julian, W.M. Cronin, and S.R. Haile Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches J Clin Oncol 25 2007 5113 5120
28. F.I.G.O. Cancer Committee. Staging announcement Gynecol Oncol 25 1986 383 385
29. L. Verleye, P.B. Ottevanger, W. van der Graaf, N.S. Reed, and I. Vergote EORTC-GCG process quality indicators for ovarian cancer surgery Eur J Cancer 45 2009 517 526
30. A. du Bois, J. Rochon, J. Pfisterer, and W.J. Hoskins Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review Gynecol Oncol 112 2009 422 436
31. F. Vernooij, A.P. Heintz, P.O. Witteveen, van der Heiden-van der Loo, J.W. Coebergh, and Y. van der Graaf Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study J Natl Cancer Inst 100 2008 399 406
32. C. Marth, S. Hiebl, W. Oberaigner, R. Winter, S. Leodolter, and P. Sevelda Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic Oncology Int J Gynecol Cancer 19 2009 94 102
33. W. Oberaigner, and W. Stuhlinger Influence of department volume on cancer survival for gynaecological cancers - a population-based study in Tyrol, Austria Gynecol Oncol 103 2006 527 534
34. S. Kumpulainen, R. Sankila, A. Leminen, T. Kuoppala, M. Komulainen, and U. Puistola The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland Gynecol Oncol 115 2009 199 203
35. A. du Bois, J. Rochon, C. Lamparter, and J. Pfisterer Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer Int J Gynecol Cancer 15 2 2005 183 191
36. J. Bailey, J. Murdoch, R. Anderson, J. Weeks, and C. Foy Stage III and IV ovarian cancer in the South West of England: five-year outcome analysis for cases treated in 1998 Int J Gynecol Cancer 16 Suppl. 1 2006 25 29